{
  "compound": "Nabiximols + temozolomide",
  "condition": "CANCER_PALLIATIVE",
  "effect_size": "Large survival difference (30% absolute)",
  "study_type": "RCT",
  "source": "NORML:CANCER_RCT_005",
  "participants": "21 recurrent glioblastoma patients",
  "year": 2017,
  "notes": "CBD for Quality of Life in Glioblastoma: Phase II Trial",
  "confidence": "medium",
  "abstract": "Nabiximols + TMZ: 83% 1-year survival vs TMZ alone: 53% (historical); Median survival: 550 vs 369 days"
}